The post From our CEO appeared first on MS Australia. Source: www.msaustralia.org.au
The post New €685 million data resource to power progressive MS research appeared first on MS Australia. Source: www.msaustralia.org.au
The post Understanding depression in MS: A Q&A with Associate Professor Litza Kiropoulos appeared first on MS Australia. Source: www.msaustralia.org.au
The new revisions to the McDonald criteria for multiple sclerosis (MS) — a set of guidelines long used to diagnose the neurodegenerative condition — have increased the proportion of people […] The post ECTRIMS 2025: Updated McDonald criteria enable more MS diagnoses appeared first on…
Tweet Late Breakers ECTRIMS 2025 is now underway. Sorry it is a post on CD20 and I know some of you are abit bored by this but this actually about work we have done and it is relevant that this is ocrelizumab, if we did…
There’s nothing like the first cool mornings of fall to make you crave something warm, comforting, and just a little bit sweet. These Pumpkin Spice Oat Muffins are the perfect way to bring the flavors of the season to your … Continue reading → Source:…
The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the world’s largest congress dedicated to multiple sclerosis (MS) research and care, kicks off today […] The post ECTRIMS 2025: A ‘new era’ for diagnosis and treatment appeared first on…
Tweet Habek M, Adamec I, Gabelić T, Barun B, Krbot Skorić M. Diagnostic performance of the 2010, 2017, and 2024 McDonald criteria: clinical implications in multiple sclerosis. J Neurol. 2025 Sep 20;272(9):637. Objective: To compare the sensitivity (capacity to identify true positives), specificity (capacity to detect…
The post Official statement on MS Society South Australia & Northern Territory voluntary administration appeared first on MS Australia. Source: www.msaustralia.org.au
The U.S. Food and Drug Administration (FDA) has delayed by three months its decision on whether or not to approve Sanofi’s tolebrutinib as a treatment for multiple sclerosis (MS), pushing […] The post FDA pushes back to December its decision on Sanofi’s tolebrutinib appeared first…